anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The process of wound healing is intricate and complex, necessitating the intricate coordination of various cell types and bioactive molecules. Despite significant advances, challenges persist in achieving accelerated healing and minimizing scar formation. Herein, a multifunctional hydrogel engineered via dynamic Schiff base crosslinking between oxidized dextran and quaternized chitosan, reinforced with reduced graphene oxide (rGO) is reported. The resulting OQG hydrogels demonstrated injectability to aid in conforming to irregular wound geometries, rapid self-healing to maintain structural integrity and adhesion for intimate integration with wound beds. Moreover, the developed hydrogels possessed antioxidant and antibacterial activities, mitigating inflammation and preventing infection. The incorporation of conductive rGO further facilitated the transmission of endogenous electrical signals, stimulating cell migration and tissue regeneration. In addition, the polydopamine-encapsulated asiaticoside (AC@PDA) nanoparticles were encapsulated in OQG hydrogels to reduce scar formation during in vivo evaluations. In vitro results confirmed the histocompatibility of the hydrogels to promote cell migration. The recovery of the full-thickness rat wounds revealed that these designed OQG hydrogels with the incorporation of AC@PDA nanoparticles could accelerate wound healing, reduce inflammation, facilitate angiogenesis, and minimize scarring when implemented. This multifunctional hydrogel system offers a promising strategy for enhanced wound management and scarless tissue regeneration, addressing the multifaceted challenges in wound care.
Biomimetic tumor microenvironment models bridge the gap between in vitro and in vivo systems and serve as a useful way to address the modeling challenge of how to recreate the cell and system complexity associated with real tissues. Our laboratory has developed an ex vivo rat mesentery culture model, which allows for simultaneous investigation of blood and lymphatic microvascular network remodeling in an intact tissue environment. Given that angiogenesis and lymphangiogenesis are key contributors to the progression of cancer, the objective of this study was to combine tissue and tumor spheroid culture methods to establish a novel ex vivo tumor spheroid-tissue model by verifying its use for evaluating the effects of cancer cell behavior on the local microvascular environment. H1299 or A549 tumor spheroids were formed via hanging drop culture and seeded onto rat mesenteric tissues harvested from adult male Wistar rats. Tissues with transplanted spheroids were cultured in serum-free media for 3 to 5 days. PECAM, NG2, CD11b, and αSMA labeling identified endothelial cells, pericytes, immune cells, and smooth muscle cells, respectively. Time-lapse imaging confirmed cancer cell type specific migration. In addition to increasing PECAM positive capillary sprouting and LYVE-1 positive endothelial cell extensions indicative of lymphangiogenesis, tumor spheroid presence induced the formation of lymphatic/blood vessel connections and the formation of hybrid, mosaic vessels that were characterized by discontinuous LYVE-1 labeling. The results support the application of a novel tumor spheroid microenvironment model for investigating cancer cell-microvascular interactions.
BACKGROUND: Acellular dermal matrices (ADMs) are frequently employed in immediate prosthesis-based breast reconstruction (iPBR) to provide structural support. Despite differences in ADM derivatives, few studies directly compare their outcomes in the setting of iPBR. We sought to conduct a large head-to-head study comparing 3 ADMs used across our institution.
METHODS: A multicenter retrospective review of patients undergoing iPBR with SurgiMend PRS (fetal bovine-derived; Integra Lifesciences, Princeton, NJ), AlloDerm (human-derived; LifeCell Corp, Bridgewater, NJ), or DermACELL (human-derived; Stryker Corp, Kalamazoo, MI) between January 2014 to July 2022 was performed. Primary outcomes included rates of unplanned explantation and total reconstructive failure. Secondary outcomes included 90-day postoperative complications and long-term rates of capsular contracture development.
RESULTS: A total of 738 patients (1228 breasts) underwent iPBR during the study period; 405 patients received DermACELL (54.9%), 231 received AlloDerm (31.3%), and 102 received SurgiMend PRS (13.8%). Rates of short-term complications, total reconstruction failure, reoperation within 90 days, capsular contracture, and unplanned explantation were comparable. These findings remained true upon multivariate analysis accounting for baseline differences between cohorts, whereby ADM type was not an independent predictor of any outcome of interest. Conversely, factors such as body mass index, diabetes mellitus, smoking history, neoadjuvant and adjuvant chemotherapy, adjuvant radiation, skin-sparing mastectomy, Wise pattern and periareolar incisions, use of tissue expanders, and a subpectoral plane of insertion were significant predictors of postoperative complications.
CONCLUSION: Low rates of complications support the equivalency of fetal bovine and human-derived ADMs in iPBR. Patient characteristics and operative approach are likely more predictive of postoperative outcomes than ADM derivative alone.
The present invention relates to a composition for alleviating skin wrinkles containing a mixture of an Ulmus davidiana var. japonica extract and a Cornus officinalis extract as an active component. More specifically, the mixture of the Ulmus davidiana var. japonica extract and the Cornus officinalis extract is effective for alleviating wrinkles. Therefore, the composition of the present invention containing the Ulmus davidiana var. japonica extract and the Cornus officinalis extract can be usefully used as a material for functional cosmetics or health functional food for alleviating skin wrinkles.
Patients underwent surgical repair of right ventricular hypertrophic congenital heart disease. Each patient will undergo three 60-min trials with 30-min wash out during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
Tumor-related epilepsy (TRE) is a frequent and major consequence of brain tumors. Management of TRE is required throughout the course of disease and a deep understanding of diagnosis and treatment is key to improving quality of life. Gross total resection is favored from both an oncologic and epilepsy perspective. Shared mechanisms of tumor growth and epilepsy exist, and emerging data will provide better targeted therapy options. Initial treatment with antiseizure medications (ASM) in conjunction with surgery and/or chemoradiotherapy is typical. The first choice of ASM is critical to optimize seizure control and tolerability considering the effects of the tumor itself. These agents carry a potential for drug-drug interactions and therefore knowledge of mechanisms of action and interactions is needed. A review of adverse effects is necessary to guide ASM adjustments and decision-making. This review highlights the essential aspects of diagnosis and treatment of TRE with ASMs, surgery, chemotherapy, and radiotherapy while indicating areas of uncertainty. Future studies should consider the use of a standardized method of seizure tracking and incorporating seizure outcomes as a primary endpoint of tumor treatment trials.
Period 1 for all patients: IKERVIS® (1mg/ml CsA). Instillation of one drop in each affected eye, once daily at bedtime. From Baseline for the first 12 months of treatment.
The routine follow-up conducted by the diabetes education unit will continue for the study group, and no interventions will be made as part of the research. The study group will undergo a pre-test at the beginning of the study, a follow-up test at the 3rd month, and a post-test at the 6th month as part of the research.
Described herein are mutant  pneumoviruses  comprising a nucleotide sequence which encodes a mutated zinc binding motif in an M2-1 protein of the  pneumovirus , wherein the zinc binding motif is mutated relative to wild-type  pneumovirus . The mutant  pneumoviruses  described herein grow to high titer in cell culture, are genetically stable, are attenuated in vitro and in vivo, and are highly immunogenic. Also described herein are vaccines and vaccine compositions comprising the live attenuated mutant  pneumoviruses . Vaccine compositions can further comprise a pharmaceutically acceptable carrier, vehicle, excipient, and/or adjuvant. Methods for inducing a protective immune response in a subject against a  pneumovirus  infection are also described and disclosed. The vaccine compositions and methods described herein can be used to prevent  metapneumovirus  and respiratory syncytial virus infection in humans, respiratory syncytial virus infection in cattle, avian  metapneumovirus  infection in various avian species, and pneumonia virus of mice in rodents.
In an embodiment, the present disclosure pertains to a method of treating or preventing  C. difficile  infections. In some embodiments, the method includes administering an antitoxin to a subject in need thereof. In some embodiments, the antitoxin includes a designed ankyrin repeat protein (DARPin). In an additional embodiments, the present disclosure pertains to a composition including an antitoxin for treating or preventing  C. difficile  infections. In some embodiments, the anti-toxin includes a DARPin. In some embodiments, the anti-toxin is a monomeric or dimeric DARPin for the neutralization of  Clostridium difficile  toxin B (TcdB).
For the second part (validation study) we will administered F-CISS, F-PWES, F-DASH, F-HFS, F-SF 36 questionnaires and a pain VAS to a population of in and outpatients with hand injuries. We aim to include patients during one year for a total expected of 100 patients.
Following the advent of direct-acting antivirals (DAAs), hepatitis C virus (HCV) infection can be cured in almost all infected patients. This has led to a number of clinical questions regarding the optimal management of the millions of patients cured of HCV. This position statement provides specific guidance on the appropriate follow-up after a sustained virological response in patients without advanced fibrosis, those with compensated advanced chronic liver disease, and those with decompensated cirrhosis. Guidance on hepatocellular carcinoma risk assessment and the management of extrahepatic manifestations of HCV is also provided. Finally, guidance is provided on the monitoring and treatment of reinfection in at-risk patients. The recommendations are based on the best available evidence and are intended to help healthcare professionals involved in the management of patients after treatment for HCV.
Iodophor-containing suppositories are provided with improved rate of iodine release from the suppository. The suppository composition comprises an iodophor, a water soluble suppository base, at least one water soluble sugar having a molecular weight of between about 90 and 550, and water in an amount of at least about 30% by weight. The molecular weight of the sugar is preferably between about 150 and 370. The preferred iodophors are providone iodine and polydextrose iodine. The preferred suppository bases are gelling polysaccharides and the preferred sugars are monosaccharides, disaccharides and sugar alcohols. The rate of iodine release is improved because of the high concentration of water together with the presence of the low molecular weight sugar.
BACKGROUND: The purpose of this study was to evaluate the effects of β-adrenoceptors (ADRBs) on the urothelial inflammation and zonula occludens (ZO) in a rat PBOO model and in an in vitro model.
METHODS: The PBOO model was established by ligating the bladder neck of rats. Twenty rats were divided into 4 groups: sham operation, PBOO + normal saline, PBOO + ADRB2 agonist, PBOO + ADRB3 agonist. PBOO rats were with treated with ADRBs agonists for 3 weeks. Human urothelial cells (HUCs) were subjected to ADRBs agonist treatment or hydrostatic pressure in an in vitro model.
RESULTS: In the PBOO group, there was a significant increase in the expression of MCP-1, IL-6 and RANTES compared to the sham group. By contrast, there was a post-PBOO decline in the expression of ZO-1 and ZO-2 in the urothelium. ADRB2 or ADRB3 agonists exhibited downregulated inflammatory cytokine expression and increased ZO expression in the PBOO model. The regulation of inflammation and ZO by ADRB2 and ADRB3 agonists in an in vitro model was found consistent with that in the PBOO model. Moreover, RhoA and ROCK inhibitors suppressed the expression of hydrostatic pressure-induced inflammatory cytokines. Additionally, RhoA agonist reversed the inhibitory effect of ADRBs agonists on the inflammatory secretion from HUCs.
CONCLUSIONS: ADRB2 and ADRB3 agonists increased ZO protein expression in HUCs in a rat PBOO model and in an in vitro model. Furthermore, ADRB2 and ADRB3 agonists inhibited the secretion of inflammatory cytokines from HUCs by regulating the RhoA/ROCK signaling pathways.
A method of producing proteins exhibiting antigenicity of hbeag or hbsag and compositions containing a plurality of proteins. Protein with antigenicity hbeag is produced by culture of vertebrate cells transfected with a dna molecule recombinant having the sequence gene precore-core hbv, operably linked to a able vector express the gene in these cells, protein secretion environmental and recovery of it. Protein with antigenicity hbsag obtained by a similar protocol except that the dna sequence contains the sequence recombinant gene pres1-pres2-s hbv. Compositions using multiple porteinas se obttienen cells transfected with dna molecules recombinant outlined above. These proteins and compositions are useful for detecting the presence of hbeag or antibodies against hbeag in a body sample. (Machine-translation by Google Translate, not legally binding)
The long-term goal of this project is to develop an effective conservative treatment protocol that is easily accessible. The objective of this application is to determine if patients who are treated with Mulligan Concept manual therapy experience immediate and significant changes in pain and function. Our specific aims are: In women with PPGP, 1.) Determine if Mulligan Concept treatment produces immediate changes in pain and function, 2.) Determine whether the Mulligan Concept immediately restores or alters dysfunctional gait characteristics and pelvic girdle motor control, and 3.) Identify factors that mathematically predict treatment outcome. Our central hypothesis is that restoration of lumbopelvic positioning will result in immediate decrease in pain, increase in function, and improved gait mechanics.

Volunteers in the 20th-34th week of pregnancy, ages 20-45 years, who are experiencing PPGP will be screened and randomly assigned into treatment or placebo group based on age, weight, height, gestational week and number of pregnancies. All participants will undergo a standardized examination, complete patient reported outcome measures, and perform a walking gait, sit to stand, and active straight leg raise tasks. Kinematic, kinetic, and EMG recordings will be taken during performance of the tasks. The participants of the treatment group will receive a Mulligan Concept evaluation and treatment. Participants in the placebo group will receive only the Mulligan Concept evaluation. Participants will then repeat the same tasks and measures. The study will be conducted under a randomized triple blinded placebo trial design; the patients, researchers, and treating clinician will be blinded to group assignment. Independent sample t-tests will be conducted to determine if significant differences exist between the intervention and placebo group across several dependent variables. Regression analysis will be conducted in order to determine if intake factors mathematically predict treatment outcome.
The invention discloses a preparation for treating psoriasis caused by yang deficiency, external cold and skin blood stasis and heat and a preparation method thereof, belonging to the technical field of Chinese herbal medicines. In the prescription, the aconite and the asarum have the effects of warming yang and strengthening body resistance so as to dissipate external cold and remove skin heat stasis, the ephedra has the effect of dissipating the skin heat stasis due to pungent and warm property, the buffalo horn, the gardenia, the lithospermum, the red paeony root and the suberect spatholobus stem have the effect of clearing the skin heat stasis, and the raw licorice has the effects of detoxifying and harmonizing the other drugs. The whole formula treats both exterior and interior, combines cold and warm, and simultaneously regulates deficiency and excess, thereby restoring the balance of yin and yang of the organism. Therapeutic method: to warm yang, release exterior syndrome, cool blood and clear heat. The main treatment symptoms are: the skin damage of autumn and winter recurs or aggravates after a long time, the erythema is light or red, the scales are thin, the patient is intolerant of cold and intolerant of cold, the hands and feet are not warm, or the diet is poor, and the stool is thin. A pale and swollen tongue with thin and white coating and a deep and weak pulse. Is used for treating the psoriasis which is caused by yang deficiency, external cold and skin stasis heat syndrome, namely deficiency cold of body and skin stasis heat, and skin damage relapse or aggravation after coming in autumn and winter.
Treatment of mild to moderate malaria in pediatric patients caused by mefloquine-susceptible strains of P. falciparum

Dosage: 20 to 25 mg/kg body weight. Splitting the total therapeutic dose into 2 doses taken 6 to 8 hours apart may reduce the occurrence or severity of adverse effects. The pediatric dose should not exceed the adult dose.

Experience with mefloquine in pediatric patients weighing less than 20 kg is limited. The drug should not be taken on an empty stomach and should be administered with ample water. The tablets may be crushed and suspended in a small amount of water, milk or other beverage for administration to small children and other persons unable to swallow them whole.

If a full-treatment course with mefloquine does not lead to improvement within 48 to 72 hours, mefloquine should not be used for retreatment. An alternative therapy should be used. Similarly, if previous prophylaxis with mefloquine has failed, mefloquine should not be used for curative treatment.

In pediatric patients, the administration of mefloquine for the treatment of malaria has been associated with early vomiting. In some cases, early vomiting has been cited as a possible cause of treatment failure (see PRECAUTIONS). If a significant loss of drug product is observed or suspected because of vomiting, a second full dose of mefloquine should be administered to patients who vomit less than 30 minutes after receiving the drug. If vomiting occurs 30 to 60 minutes after a dose, an additional half-dose should be given. If vomiting recurs, the patient should be monitored closely and alternative malaria treatment considered if improvement is not observed within a reasonable period of time. 

The safety and effectiveness of mefloquine to treat malaria in pediatric patients below the age of 6 months have not been established.
OBJECTIVES: To compare the difference in the clinical efficacy on piriformis syndrome between trigger-point (TrP) acupuncture and glucocorticoid injection.
METHODS: Sixty patients with piriformis syndrome were randomly allocated to an acupuncture group (30 cases, treated with TrP acupuncture) and a control group (30 cases, treated with glucocorticoid injection). In the two groups, the intervention was delivered once weekly and 2 treatments were required. Before treatment and 1 week, 1 month, 2 months and 3 months after treatment, the scores of the numerical rating scale (NRS) and Oswestry dysfunction index questionnaire (ODI), and the passive hip range of motion (PROM) were collected separately;the score of the 36-item short form of health survey (SF-36) was observed 3 months after treatment;and the administration of analgesic medication and the occurrence of adverse effects were recorded in the patients of 2 groups.
RESULTS: The scores of NRS and ODI were decreased, and PROM was increased at each time point compared with the baseline (before treatment) in both groups (P<0.05). In comparison with the control group, the scores of NRS and ODI were decreased (P<0.01, P<0.05) and the range of hip internal rotation (HIR) was increased in the acupuncture group 2 and 3 months after treatment (P<0.01). Three months after treatment, the scores for physiological function, body pain, and vitality of SF-36 in the acupuncture group were higher than those of the control group (P<0.05). The number of patients with analgesic drugs was less (P<0.05) in the acupuncture group than that in the control group in 2 and 3 months after treatment. During treatment and in follow-up stage, no serious adverse reactions occurred in the patients of 2 groups.
CONCLUSIONS: The clinical effect of TrP acupuncture is similar to that of glucocorticoid injection on piriformis syndrome in 1 month after treatment. In 2 months after treatment, TrP acupuncture is markedly effective for attenuating pain and the functional impairment of the lower limbs, improving the quality of life and reducing the use of analgesic drugs in comparison with glucocorticoid injection.